NVO vs RYTM
NVO: A global leader in diabetes and obesity care, pioneering breakthrough GLP-1 receptor agonist therapies for chronic disease management. RYTM: Rhythm Pharmaceuticals is a precision medicine company developing targeted MC4R agonist therapies for patients living with rare, severe obesity-related neuroendocrine diseases.
Side-by-side fundamentals
| Metric | NVO | RYTM | Edge |
|---|---|---|---|
| Price as of 2026-08-04 close | $44.28 | $105.78 | |
| Market cap as of 2026-08-05 | $206.5B | $7.2B | |
| P/E as of 2026-08-05 | 10.99 | n/a | |
| PEG as of 2026-08-05 | 16.16 | -2.86 | RYTM lower |
| Net margin as of 2026-08-05 | +37.2% | -93.3% | NVO higher |
| Gross margin as of 2026-08-05 | +81.8% | +89.4% | RYTM higher |
| Operating margin as of 2026-08-05 | +45.3% | -90.9% | NVO higher |
| ROE as of 2026-08-05 | +66.4% | -86.5% | NVO higher |
| ROA as of 2026-08-05 | +23.3% | -45.0% | NVO higher |
| Debt / equity as of 2026-08-05 | 0.72 | 0.46 | RYTM lower |
| Revenue growth (YoY) as of 2026-08-05 | +8.1% | +58.7% | RYTM higher |
| Revenue CAGR (3y) SEC XBRL | +20.4% | +100.2% | RYTM higher |
| Dividend yield as of 2026-08-05 | +3.8% | n/a | |
| Beta as of 2026-08-05 | 1.84 | 2.00 | |
| 1-year return as of 2026-08-04 close | -9.3% | +17.2% | RYTM higher |
Fundamentals: market data, as of 2026-08-05. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-04.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.